De novo PD-1-expressing large B-cell lymphoma outside the setting of CLL: possible origin from CD5 + /PD-1 + regulatory B-cell subset

2021 ◽  
Author(s):  
Kristina Doytcheva ◽  
Angela Lager ◽  
Girish Venkataraman
Keyword(s):  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Cell Subset ◽  
B Cell Lymphoma ◽  
Regulatory B Cell ◽  
Large B Cell Lymphoma ◽  
Large B Cell

De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome

1999 ◽  
Vol 105 (4) ◽  
pp. 1133-1139 ◽  
Author(s):  
Motoko Yamaguchi ◽  
Toshiyuki Ohno ◽  
Kouji Oka ◽  
Masanori Taniguchi ◽  
Motohiro Ito ◽  
...  
Keyword(s):  
B Cell ◽  
Clinical Characteristics ◽  
De Novo ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Therapeutic Outcome ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Analysis of chromosomal imbalances in de novo CD5-positive diffuse large-B-cell lymphoma detected by comparative genomic hybridization

2003 ◽  
Vol 39 (1) ◽  
pp. 77-81 ◽  
Author(s):  
Sivasundaram Karnan ◽  
Hiroyuki Tagawa ◽  
Ritsuro Suzuki ◽  
Miyuki Suguro ◽  
Motoko Yamaguchi ◽  
...  
Keyword(s):  
B Cell ◽  
Comparative Genomic Hybridization ◽  
De Novo ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Comparative Genomic ◽  
Genomic Hybridization ◽  
Chromosomal Imbalances ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas

Oncotarget ◽  
2017 ◽  
Vol 8 (20) ◽  
pp. 33487-33500 ◽  
Author(s):  
Naoko Tsuyama ◽  
Daisuke Ennishi ◽  
Masahiro Yokoyama ◽  
Satoko Baba ◽  
Reimi Asaka ◽  
...  
Keyword(s):  
T Cell ◽  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
B Cell Lymphoma ◽  
Cell Marker ◽  
Large B Cell Lymphoma ◽  
Marker Expression ◽  
Large B Cell

scholarly journals Prognostic significance of CXCR4 and mTOR expression in diffuse large B-cell lymphoma patients

2019 ◽  
Vol 9 (1) ◽  
pp. 7
Author(s):  
Rasha Haggag ◽  
Naglaa A. Mostafa ◽  
Marwa Nabil ◽  
Hala A. Shokralla ◽  
Neveen F. H. Sidhom
Keyword(s):  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Prognostic Significance ◽  
B Cell Lymphoma ◽  
Poor Response ◽  
Cxcr4 Expression ◽  
Response To Treatment ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Background: The aim of this study was to investigate the prognostic role of mammalian target of Rapamycin (mTOR) and C-X-C chemokine receptor type 4 (CXCR4) in diffuse large-B-cell lymphoma (DLBCL) patients.Patients and methods: This retrospective study was collected data from 64 de novo DLBCL patients, who received standardized R-CHOP therapy at two oncology centers. CXCR4 and mTOR expressions were assessed by immunohistochemistry.Results: Out of the 64 DLBCL patients, 40 patients were positive for CXCR4 (62.5%) and 35 patients for mTOR (54.7%) expressions. CXCR4 expression was positively correlated with mTOR expression (r = 0.7; p < .001). While mTOR expression was significantly associated with high lactate dehydrogenase level (p = .03) and number of extranodal sites one or more (p =.02), CXCR4 expression was significantly associated with high IPI score (p < .001) and ECOG PS (p = .005). Furthermore, theexpression levels of mTOR and CXCR4 were significantly associated with older ages and poor response to treatment (p = .04, <.001 and .04, .03, respectively). After a median Follow up of 22 months, mean ± SD overall survival (OS) was 65.391 ± 4.705. Kaplan–Meier analysis showed that patients positive for mTOR and CXCR4 expression had shorter DFS (p = .01 & .02) and OS (p = .02 & .04). Multivariate analysis showed that CXCR4 and mTOR positivity is an independent prognostic factor for significantly poorer DFS (p = .03, and .02 respectively) but not for OS (p = .09 and .08 respectively) in the DLBCL pateints.Conclusion: Our results indicate that the expression of CXCR4 and mTOR may be poor prognostic biomarkers in DLBCL.

scholarly journals Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes With Prognosis

2015 ◽  
Vol 33 (12) ◽  
pp. 1379-1388 ◽  
Author(s):  
Karen Dybkær ◽  
Martin Bøgsted ◽  
Steffen Falgreen ◽  
Julie S. Bødker ◽  
Malene K. Kjeldsen ◽  
...  
Keyword(s):  
B Cell ◽  
Classification System ◽  
Cell Lymphoma ◽  
Positive Impact ◽  
Cell Subset ◽  
Progression Free Survival ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
The Impact ◽  
Large B Cell

Purpose Current diagnostic tests for diffuse large B-cell lymphoma use the updated WHO criteria based on biologic, morphologic, and clinical heterogeneity. We propose a refined classification system based on subset-specific B-cell–associated gene signatures (BAGS) in the normal B-cell hierarchy, hypothesizing that it can provide new biologic insight and diagnostic and prognostic value. Patients and Methods We combined fluorescence-activated cell sorting, gene expression profiling, and statistical modeling to generate BAGS for naive, centrocyte, centroblast, memory, and plasmablast B cells from normal human tonsils. The impact of BAGS-assigned subtyping was analyzed using five clinical cohorts (treated with cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP], n = 270; treated with rituximab plus CHOP [R-CHOP], n = 869) gathered across geographic regions, time eras, and sampling methods. The analysis estimated subtype frequencies and drug-specific resistance and included a prognostic meta-analysis of patients treated with first-line R-CHOP therapy. Results Similar BAGS subtype frequencies were assigned across 1,139 samples from five different cohorts. Among R-CHOP–treated patients, BAGS assignment was significantly associated with overall survival and progression-free survival within the germinal center B-cell–like subclass; the centrocyte subtype had a superior prognosis compared with the centroblast subtype. In agreement with the observed therapeutic outcome, centrocyte subtypes were estimated as being less resistant than the centroblast subtype to doxorubicin and vincristine. The centroblast subtype had a complex genotype, whereas the centrocyte subtype had high TP53 mutation and insertion/deletion frequencies and expressed LMO2, CD58, and stromal-1–signature and major histocompatibility complex class II–signature genes, which are known to have a positive impact on prognosis. Conclusion Further development of a diagnostic platform using BAGS-assigned subtypes may allow pathogenetic studies to improve disease management.

scholarly journals De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course

2019 ◽  
Vol 7 ◽  
pp. 232470961989354
Author(s):  
Preethi Ramachandran ◽  
Sonu Sahni ◽  
Jen C. Wang
Keyword(s):  
Gastrointestinal Tract ◽  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Prognostic Index ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Gastrointestinal Lymphomas ◽  
Large B Cell

The gastrointestinal tract is a common extranodal site for lymphomas. However, primary gastrointestinal lymphomas are rare. Diffuse large B-cell lymphomas (DLBCL) are the most commonly encountered type in the gastrointestinal tract. Most of the DLBCL are CD5 negative. CD5+ DLBCL is very rare and a poor prognostic subtype of lymphoma. We report a rare case of primary small bowel CD5+ DLBCL that evolved from being a localized low International Prognostic Index–scored disease into an advanced and aggressive disease primarily dictated by the presence of CD5 antigen positivity.

De novo CD5-positive primary cardiac diffuse large B-cell lymphoma diagnosed by pleural fluid cytology

2012 ◽  
Vol 42 (3) ◽  
pp. 259-267 ◽  
Author(s):  
Adina M. Cioc ◽  
José Jessurun ◽  
Gregory M. Vercellotti ◽  
Stefan E. Pambuccian
Keyword(s):  
B Cell ◽  
Pleural Fluid ◽  
De Novo ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Large B Cell ◽  
Fluid Cytology

De Novo CD5+ Diffuse Large B-Cell Lymphoma With Cutaneous Involvement

2014 ◽  
Vol 19 (4) ◽  
pp. 200-203 ◽  
Author(s):  
Dmitry V. Kazakov ◽  
Pavel Jindra ◽  
Werner Kempf ◽  
Boris Kreuzberg ◽  
Ondrej Sebera ◽  
...  
Keyword(s):  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cutaneous Involvement ◽  
Large B Cell Lymphoma ◽  
Large B Cell

scholarly journals Recent advances in de novo CD5+diffuse large B cell lymphoma

2013 ◽  
Vol 88 (9) ◽  
pp. 798-802 ◽  
Author(s):  
Preetesh Jain ◽  
Luis E. Fayad ◽  
Andreas Rosenwald ◽  
Ken H. Young ◽  
Susan O'Brien
Keyword(s):  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Recent Advances ◽  
Large B Cell

scholarly journals Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

Blood ◽  
2017 ◽  
Vol 129 (23) ◽  
pp. 3059-3070 ◽  
Author(s):  
Steven Le Gouill ◽  
René-Olivier Casasnovas
Keyword(s):  
B Cell ◽  
De Novo ◽  
Cell Lymphoma ◽  
Standardized Uptake Value ◽  
B Cell Lymphoma ◽  
Daily Practice ◽  
Predictive Tool ◽  
Predictive Values ◽  
Large B Cell Lymphoma ◽  
Large B Cell

Abstract 18F-Fluorodeoxyglucose–positron emission tomography (FDG-PET) has become a central tool for both accurate initial staging and determination of prognosis after treatment of diffuse large B-cell lymphoma (DLBCL). However, the role of PET during treatment (iPET) in daily practice remains a matter of significant debate. This perspective reviews the published studies on iPET in DLBCL, including the methods used to analyze iPET, its timing, and studies of iPET-driven therapy to illuminate where daily practice may benefit from the use of iPET. When performed after 2 and/or 4 courses of immunochemotherapy, iPET has a very good negative predictive value, utilizing both visual (qualitative) and semiquantitative methods. The visual method accurately predicts outcome for patients with limited disease. The semiquantitative method, eg, the change of the difference of maximum standardized uptake value (ΔSUVmax), is for patients with advanced DLBCL, for whom iPET identifies patients with very good outcome with continuation of standard therapy. A low ΔSUVmax also helps identify patients with a risk for relapse averaging 50% and warrants review of their scheduled therapy. To date, no trial has demonstrated the superiority of an iPET-driven strategy in DLBCL. However, the very good negative and good positive predictive values of iPET support its use in daily practice as a better predictive tool than contrast-enhanced computed tomographic scan for therapeutic decision making.

Sign in / Sign up

Export Citation Format

Share Document